Cybin Inc., a clinical-stage neuropsychiatry company, focuses on developing psychedelic-based therapeutics for patients with mental health conditions. The company's development pipeline includes CYB003, a deuterated psilocybin analog, which is in phase 3 clinical trial to treat major depressive disorder (MDD), as well as in preclinical trials for alcohol use disorder; CYB004, a deuterated dimethyltryptamine (DMT), which is in phase 2 clinical trial for treating generalized anxiety disorders; SPL028 injectable deuterated DMT completed phase 1 clinical intramuscular and intravenous trial; SPL026 completed phase 1, 1b, and 1/2a for MDD; and CYB005, a phenethylamine derivative, which in preclinical stage to treat neuroinflammation, as well as has a research pipeline of investigational psychedelic-based compounds. The company has a strategic partnership agreement with Segal Trials to support PARADIGM, a multinational pivotal phase 3 program evaluating CYB003 for the adjunctive treatment of major depressive disorder. The company is headquartered in Toronto, Canada. Show more
Location: 100 King Street West, Toronto, ON, M5X 1C9, Canada | Website: https://www.cybin.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
183.9M
52 Wk Range
$4.81 - $13.88
Previous Close
$7.73
Open
$7.84
Volume
428,944
Day Range
$7.67 - $8.00
Enterprise Value
43.02M
Cash
135M
Avg Qtr Burn
-25.33M
Insider Ownership
207.96%
Institutional Own.
42.41%
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
CYB003 (Deuterated Psilocin Oral) Details Major Depressive Disorder (MDD) adjunct | Phase 3 Data readout | |
CYB004 (Deuterated Dimethyltryptamine Intramuscular) Details Generalized Anxiety Disorder (GAD) | Phase 2 Data readout |